Literature DB >> 11038381

Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice.

Eduardo O'Neill1, Scott L Krauss1, Janice M Riberdy1, Robert G Webster1, David L Woodland1.   

Abstract

The continual threat posed by newly emerging influenza virus strains is demonstrated by the recent outbreak of H5N1 influenza virus in Hong Kong. Currently, immunization against influenza virus infection is fairly adequate, but it is imperative that improved vaccines are developed that can protect against a variety of strains and be generated rapidly. Since humoral immunity is ineffective against serologically distinct viruses, one strategy would be to develop vaccines that emphasize cellular immunity. Here we report the successful protection of C57BL/6 mice from a lethal A/HK/156/97 (HK156) infection by immunizing first with an H9N2 isolate, A/Quail/HK/G1/97 (QHKG1), that harbours internal genes 98% homologous to HK156. This strategy also protected mice that are deficient in antibody production, indicating that the immunity is T-cell-mediated. In the course of these studies, we generated a highly pathogenic H5N1 reassortant which implicated NP and PB2 as having an important contribution to pathogenesis when present with a highly cleavable H5. These results provide the first demonstration that protective cell-mediated immunity can be established against the highly virulent HK156 virus and have important implications for the development of novel strategies for the prevention and treatment of HK156 infection and the design of future influenza vaccines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038381     DOI: 10.1099/0022-1317-81-11-2689

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  47 in total

1.  Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.

Authors:  Yuan Fang; David Banner; Alyson A Kelvin; Stephen S H Huang; Christopher J Paige; Steven A Corfe; Kevin P Kane; R Chris Bleackley; Thomas Rowe; Alberto J Leon; David J Kelvin
Journal:  J Virol       Date:  2011-11-30       Impact factor: 5.103

2.  Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus.

Authors:  Alina C Boesteanu; Nadarajan S Babu; Margaret Wheatley; Elisabeth S Papazoglou; Peter D Katsikis
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

3.  Immunogenicity of novel consensus-based DNA vaccines against avian influenza.

Authors:  Dominick J Laddy; Jian Yan; Natasha Corbitt; Gary P Kobinger; David B Weiner
Journal:  Vaccine       Date:  2007-01-30       Impact factor: 3.641

4.  Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Authors:  Carolien E van de Sandt; YingYing Dou; Stella E Vogelzang-van Trierum; Kim B Westgeest; Mark R Pronk; Albert D M E Osterhaus; Ron A M Fouchier; Guus F Rimmelzwaan; Marine L B Hillaire
Journal:  J Gen Virol       Date:  2015-04-21       Impact factor: 3.891

5.  Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.

Authors:  Chiara Agrati; Cristiana Gioia; Concetta Castilletti; Daniele Lapa; Giulia Berno; Vincenzo Puro; Fabrizio Carletti; Eleonora Cimini; Carla Nisii; Flora Castellino; Federico Martini; Maria R Capobianchi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

6.  Splenic priming of virus-specific CD8 T cells following influenza virus infection.

Authors:  Damian L Turner; Kara L Bickham; Donna L Farber; Leo Lefrançois
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

7.  Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus.

Authors:  J H C M Kreijtz; G de Mutsert; C A van Baalen; R A M Fouchier; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

8.  Protection and compensation in the influenza virus-specific CD8+ T cell response.

Authors:  Richard J Webby; Samita Andreansky; John Stambas; Jerold E Rehg; Robert G Webster; Peter C Doherty; Stephen J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-29       Impact factor: 11.205

9.  DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

Authors:  Suzanne L Epstein; Terrence M Tumpey; Julia A Misplon; Chia-Yun Lo; Lynn A Cooper; Kanta Subbarao; Mary Renshaw; Suryaprakash Sambhara; Jacqueline M Katz
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

10.  Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus.

Authors:  Rogier Bodewes; Joost H C M Kreijtz; Chantal Baas; Martina M Geelhoed-Mieras; Gerrie de Mutsert; Geert van Amerongen; Judith M A van den Brand; Ron A M Fouchier; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.